Amphastar获得林业发展局批准使用一种通用版本的Atrovent HFA,一种COPD药物,Q2 2026发射和180天独家使用。 Amphastar got FDA approval for a generic version of Atrovent HFA, a COPD drug, with a Q2 2026 launch and 180-day exclusivity.

Amphastar制药公司获得林业发展局批准其通用的Ipratoprotium Demote HFA吸入气溶胶17mcg/actuation,被认为与Boehringer Ingelheim的Atrovent HFA具有生物等值。 Amphastar Pharmaceuticals received FDA approval for its generic Ipratropium Bromide HFA Inhalation Aerosol 17mcg/actuation, deemed bioequivalent to Boehringer Ingelheim’s Atrovent HFA. 这种用于COPD维持治疗的药物将在2026年第二季度推出,并将在180天内独家使用. The drug, used for COPD maintenance treatment, will launch in Q2 2026 with 180 days of exclusivity. 在过去一年中,代行《HFA》的美国销售额约为1.12亿美元。 Atrovent HFA generated about $112 million in U.S. sales over the past year. Amphastar计划扩大其呼吸道和专用通用管道,包括肿瘤学、眼科和炎症的注射和吸入疗法。 Amphastar plans to expand its respiratory and specialty generic pipeline, including injectable and inhalation therapies for oncology, ophthalmology, and inflammatory conditions.